A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and tolerability of combined
abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary
objective is to determine the response to treatment (based on bone marrow and peripheral
blood findings). A tertiary objective is to determine the impact of therapy on health-related
quality of life (HRQOL) and patient-reported outcomes (PRO). A quaternary (scientific)
objective is to determine the impact of treatment on both hematopoietic and stromal cell
populations within the bone marrow of MDS patients.